Intelligence · Clinical Development
Pipeline search results
Programs matching “semaglutide” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 16 pipeline programs matching "semaglutide" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
NN9535-4352
NovoThirteen
While it is well-established that long-term good glycaemic control will reduce the risk of diabetic retinopathy development and progression, intensification of glycaemic control has also been associated with an initial worsening of diabetic retinopathy. This phenomenon is known as “early worsening”. The rationale of this trial is to establish the long-term effects of semaglutide on diabetic retinopathy in subjects with type 2 diabetes (T2D) using validated and standardised ophthalmic assessments. This trial is a post-authorisation safety study (PASS) conducted as a commitment to the European Medicines Agency
1 trial -
Oral semaglutide
Novo Nordisk A/S
Diabetes Mellitus, Type 2
1 trial -
Semaglutide
Novo Nordisk A/S
Overweight
1 trial -
semaglutide
Novo Nordisk A/S
Diabetes
4 trials -
Semaglutide
BRIGHT MINDS BIOSCIENCES INC.
Cocaine Use Disorder
1 trial -
Semaglutide
United Therapeutics Europe Ltd
Cardiomyopathy
1 trial -
Semaglutide (Rybelsus®)
The First People's Hospital of Lianyungang
Obesity-related Male Infertility
1 trial -
Semaglutide Pen Injector
BRIGHT MINDS BIOSCIENCES INC.
Opioid Use Disorder
1 trial -
15403/23-24
BRIGHT MINDS BIOSCIENCES INC.
Diabetes Mellitus, Type 2
1 trial -
Glucagon-like peptide-1 receptor agonist：Semaglutide
The First People's Hospital of Lianyungang
Type 2 Diabetes
1 trial -
Semaglutide
United Therapeutics Europe Ltd
Obesity
1 trial -
Semaglutide B 3.0 mg/ml PDS290
Disc Medicine
obesity
1 trial -
semaglutide combined with metformin
The First People's Hospital of Lianyungang
Osteoporosis
1 trial -
KY20220825-04
The First People's Hospital of Lianyungang
Diabetes
1 trial -
Semaglutide
GT Biopharma
Obesity (Disorder)
1 trial -
Semaglutide, 0.5 mg/mL
United Therapeutics Europe Ltd
Cognitive Change
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.